Skip to content

Online Self-Compassion Course for pALS (Compassion pALS)

Cultivating Self-Compassion Course for Persons Living With Amyotrophic Lateral Sclerosis

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05202743
Enrollment
5
Registered
2022-01-21
Start date
2021-12-17
Completion date
2022-06-01
Last updated
2022-06-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Amyotrophic Lateral Sclerosis

Brief summary

This study is designed to be a pragmatic, single-arm trial to evaluate the efficacy, implementation, and feasibility of an online ALS-specific self-compassion training program to enhance self-compassion and improve quality of life.

Detailed description

Optimizing quality of life for people with ALS is a primary goal of ALS multidisciplinary care, Therefore, it is especially important to conduct research into interventions to address the psychological needs and well-being of people with ALS. Recent studies have shown that mindfulness-based interventions promote improved quality of life for people with ALS. It is essential that such strategies as mindfulness-based interventions consider the specific needs of the ALS population and potential barriers to participation. Very few studies have evaluated mindfulness-based interventions in the ALS population and no studies to date have evaluated self-compassion people with ALS. Self-compassion has been linked to increased emotional resilience, psychological well-being, and quality of life in multiple populations. The intervention will include a 2-part workshop entitled 'Introduction to Mindful Self-Compassion for Persons Living with Amyotrophic Lateral Sclerosis.' Experience and feedback gained from the workshop will be incorporated into the format for an 8-week course in Cultivating Self-Compassion for persons living with ALS (Compassion pALS). Compassion pALS will be adapted from the Mindful Self-Compassion (MSC) Program to accommodate ALS clinical features and limit potential barriers to participation. The primary outcome will be quality of life assessed with the Amyotrophic Lateral Sclerosis Assessment Questionnaire 5 (ALSA-5). Participants will be assessed at the 2-part workshop (T0, baseline), start of the 8 week Compassion pALS course (T1 = pre-intervention); after completing the intervention (T2, post-intervention). Secondary outcomes will include Secondary outcome measures the Self-Compassion Scale Short Form (SCS-SF), Patient Health Questionnaire-9 (PHQ-9), General Anxiety Disorder-7 (GAD-7), Amyotrophic Lateral Sclerosis Functional Rating Scale-R (ALSFRS-R), Feasibility of Intervention Measure (FIM), Acceptability of Intervention Measure (AIM), and Intervention Appropriateness Measure (IAM).

Interventions

OTHERObservational for ALS patients

Open to ALS patients interested in mindfulness training.

Sponsors

Washington University School of Medicine
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum

Inclusion criteria

* Diagnosis of ALS within the last 18 months. * 18 years or older * Access to and the physical ability to use a computer with internet access with and/or without adaptive devices. * Ability to communicate and understand tasks. * A caregiver available to provide assistance. * Ability to provide informed consent

Exclusion criteria

* More than one neuropsychological impairment such as (frontotemporal dementia) which may interfere with the study procedures. * Severe medical condition that would reduce life expectancy to less than 6-12 months. * No access to a computer with internet access * Unsuitable for the study as determined by the Investigator.

Design outcomes

Primary

MeasureTime frameDescription
Quality of Life self-assessment with - Amyotrophic Lateral Sclerosis Assessment Questionnaire 5 (ALSA-5)Baseline (T1); post 8-week intervention (T2)Amyotrophic Lateral Sclerosis Assessment Questionnaire 5 (ALSAQ-5; Jenkinson et al., 2001.

Secondary

MeasureTime frameDescription
Participant functional rating self-assessmentBaseline (T1); post 8-week intervention (T2)Self-Administered ALS Functional Rating Scale-Revised (SA-ALSFRS; Montes et al., 2006)
AnxietyBaseline (T1); post 8-week intervention (T2)General Anxiety Disorder-7 (GAD-7; Spitzer et al., 2006)
DepressionBaseline (T1); post 8-week intervention (T2)Patient Health Questionnaire-9 (PHQ-9; Kroenke et al., 2002)
Self-compassionBaseline (T1); post 8-week intervention (T2)Self-Compassion Scale Short Form (SCS-SF; Raes et al., 2011)
AcceptabilityBaseline (T1); post 8-week intervention (T2)Acceptability of Intervention Measure (AIM; Weiner et al., 2017)
AppropriatenessBaseline (T1); post 8-week intervention (T2)Intervention Appropriateness Measure (IAM; Weiner et al., 2017)
Feasibility of implementationBaseline (T1); post 8-week intervention (T2)Feasibility of Intervention Measure (FIM; Weiner et al., 2017)

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026